Celcuity Inc. (CELC)
Celcuity Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Minneapolis, MN, US. The stock last traded at $79.99, down 4.89% on the session, giving a market capitalisation of $3.90B. On trailing twelve-month figures it carries a trailing P/E of -18.65, a net margin of 0.0%. Its beta of 0.16 implies it has historically moved less than the broad market.
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Celcuity Inc. is most often compared with the following Healthcare names: